#United States #Oklahoma City #blood pressure #Biozen #BP1000

Biozen's Groundbreaking Cuffless Blood Pressure Technology

Biozen, a cutting-edge digital health company, has achieved a significant milestone in the medical technology field with the FDA's recent clearance of their BP1000 device. This achievement marks the arrival of the first cuffless blood pressure monitor in the United States capable of producing clinical-grade readings without the need for traditional cuffs or calibration.

Innovative Design and Technology

The BP1000 is a revolutionary device designed for individuals frustrated with conventional blood pressure monitoring methods. It utilizes an innovative approach that allows users to obtain accurate blood pressure readings through a simple fingertip press. This technique is groundbreaking as it eliminates the need for the cumbersome and uncomfortable cuffs typically associated with blood pressure measurements.

CEO Dikran Tourian expressed the company’s mission to make regular blood pressure monitoring more accessible to the millions of Americans affected by hypertension. Nearly half of U.S. adults experience this condition, and many are deterred from monitoring their pressure due to the inconvenience of traditional methods.

The BP1000 utilizes sophisticated technology that combines pressure sensing and photoplethysmography (PPG), an optical method that detects variations in blood volume. As users gently press on the device, it measures the pressure directly at the fingertip and computes blood pressure using advanced algorithms. This direct approach negates the need for prior calibration against cuff-based measurements, which has been a significant limitation of prior cuffless designs.

Clinical Validations and Standards

In validation against the ISO 81060-2:2018, the international standard for non-invasive blood pressure devices, the BP1000 demonstrated equivalency to the traditional cuff-based methods. This rigorous validation reassures medical professionals of its reliability and accuracy. Dr. Omer Inan, Chief Scientific Officer at Biozen, emphasized the importance of their direct measurement technique, stating, "The BP1000 isn't built on black box estimation — it's grounded in the same principles of blood pressure assessment established over decades."

Expert Endorsements

Biozen's innovation garnered attention from the medical community, with doctors like Kenneth Civello, MD, commending its accuracy in measuring blood pressure rather than estimating it. Clinicians have expressed a longstanding need for more accessible and effective blood pressure monitoring solutions, and BP1000 could be the answer. Civello noted, "The distinction of measuring versus estimating is crucial and justifies the FDA clearance as a meaningful advancement in this sector."

Road Ahead: Phased Rollout

As they gear up for wider distribution, Biozen is implementing a phased approach for bringing the BP1000 to the U.S. market. An early access program is currently available for healthcare providers, partners, and early adopters eager to experience this novel technology. The expected broad commercial launch is planned for late 2026.

The company is prioritizing scaling its manufacturing processes and forging clinical and commercial partnerships while integrating this advanced sensing platform into future devices.

Enhancing Hypertension Care

Dikran Tourian highlighted a primary barrier in hypertension care — regular monitoring. Many patients neglect to check their blood pressure regularly due to the hassle of traditional cuffs. The compact, user-friendly design of the BP1000 addresses this challenge, promoting greater compliance and allowing individuals to monitor their blood pressure conveniently and frequently. "This small, simple, and portable device significantly alters the compliance landscape — enabling patients to measure their pressure wherever they are, thus fostering more consistent use," he said.

About Biozen

Headquartered in Oklahoma City with research and development in Atlanta, Biozen is a privately held company committed to reshaping how blood pressure is monitored globally. With over 68 patents secured, their BP1000 platform showcases the future of medical technology, promising a new era in patient care.

Consumers and medical professionals interested in the BP1000 can find more information and request early access at biozen.com. Through unprecedented innovation, Biozen is poised to redefine how the world measures blood pressure.